Short communication: Distribution of psychotropic drugs into lipoproteins by Serkland, Trond T. et al.
Therapeutic Drug Monitoring Publish Ahead of Print
DOI: 10.1097/FTD.0000000000000660
 
Short communication: Distribution of psychotropic drugs into lipoproteins 
 
Trond Trætteberg Serkland, MD1; Jan Schjøtt, PhD1,2; Jon Andsnes Berg, MD1; Lars 
Herfindal, PhD3; Bettina Riedel, PhD1,2; Silje Skrede, PhD1,2 
 
1Section of Clinical Pharmacology, Department of Medical Biochemistry and Pharmacology, 
Haukeland University Hospital, Bergen, Norway 
2Department of Clinical Science, University of Bergen, Bergen, Norway 




Trond Trætteberg Serkland 
Section of Clinical Pharmacology 
Department of medical biochemistry and pharmacology 
Haukeland University Hospital 
Jonas Lies Vei 65, Postboks 1400, 5021 Bergen, Norway  
e-mail trond.tretteberg.serkland@helse-bergen.no 
Conflicts of Interests 





Copyright  2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Abstract 
AIM: The aim of this pilot study was to investigate whether psychotropic drugs frequently 
analyzed in a routine therapeutic drug monitoring (TDM) laboratory bind to low density 
lipoproteins/very low-density lipoproteins (LDL/VLDL) in human serum.  
METHODS: Drug concentrations in 20 serum sample pools containi g one psychotropic 
drug each, and in the LDL/VLDL fractions extracted from the same samples, were measured 
by triple quadrupole liquid chromatography tandem mass spectrometry (LC-MS/MS). The 
membrane permeability of the drugs was measured using a Parallel Artificial Membrane 
Permeability Assay (PAMPA). 
RESULTS: Out of the 20 antidepressants, antipsychotics and antiepileptics examined, seven 
drugs were detected in both the pooled serum samples and in the LDL/VLDL fraction. 
Binding of drugs to LDL/VLDL significantly correlated with high octanol:water partition 
coefficient (logP), high degree of protein binding (PB) and a low polar surface area (PSA). 
The drugs found in LDL/VLDL, with the exception of aripiprazole, were also characterized 
by high or intermediate membrane permeability.  
CONCLUSIONS: The present results indicate that psychotropic drugs with certain 
characteristics bind to LDL/VLDL in blood. This further implies that lipoproteins could play 
an important role in drug transport. 
KEYWORDS: Lipoproteins, psychotropic drugs, therapeutic drug monitoring (TDM), 
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Introduction 
In pharmacology, the currently accepted dogma is that drugs are transported in the blood 
either bound to proteins or in an unbound form, and that only the latter is able to exert the 
desired effect by, for instance, penetrating the endothelium to reach the target cells. In 
therapeutic drug monitoring (TDM), the total amount of drug in blood, i.e. the sum of 
protein-bound and unbound substance, is most commonly measured.  
During the past decades, scattered studies have indicate  that psychotropic drugs may not 
only bind to the traditional drug transport proteins (albumin, α-1-acid glycoprotein), but also 
to lipoproteins.1-11 Recent preclinical experiments showed that antiplatelet and antiarrhythmic 
agents can bind to LDL/VLDL, which influences the pharmacokinetics of these drugs, partly 
due to LDL receptor-mediated uptake of lipoprotein-bound drugs into hepatocytes.12 This 
was described as a fundamental new concept in pharmacokinetics.  
Psychotropic drugs are frequently prescribed due to a high prevalence of psychiatric diseases, 
but are associated with interactions and metabolic adverse effects (e.g. weight gain, 
cardiovascular disease).13, 14 Furthermore, several antipsychotic agents, such as quetiapine, 
olanzapine and clozapine, have been shown to increase the risk of hyperlipidemia.15 A 
potential association with lipoproteins is therefor f particular interest with regard to 
psychotropic drugs. In theory, such drugs can potentiate their own delivery to target tissues 
through their lipogenic adverse effects.  
The main physiological role of lipoproteins is to transport lipids such as cholesterol and 
triglycerides through the hydrophilic environment of he circulatory system. Lipoproteins are 
classified based on their density, from the lowest density, the chylomicrons, to very low 
density lipoproteins (VLDL), low density lipoproteins (LDL) and finally high density 
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lipoproteins can also carry certain lipophilic compounds such as fat-soluble vitamins and 
xenobiotics like endocrine-disrupting chemicals.16-18  
In this pilot study, we selected a group of psychotropic drugs frequently analyzed in our 
routine TDM laboratory to examine distribution to LD /VLDL. Drug concentrations were 
measured in pooled serum samples, and in isolated LDL/VLDL fractions from the same 
samples. To further investigate possible mechanisms for drug-lipoprotein association, we 
measured if the drugs could cross biological membranes using a Parallel Artificial Membrane 
Permeability Assay (PAMPA) kit. The results were correlated with the physico-chemical 
properties of the drugs to reveal potential characteristics of molecules found in the lipoprotein 
fraction.  
 
Materials and Methods 
LDL/VLDL ISOLATION 
By the use of our own in-house data on drugs, which are monitored by TDM, we identified 
20 of the most frequently analyzed drugs (antiepileptics, antipsychotics and antidepressants). 
TDM serum samples no longer eligible for routine analysis (i.e. after 1 week storage for 
potential reanalysis) containing the drug in question were pooled to achieve the sufficient 
sample volume for LDL/VLDL extraction (2 mL). One pool was created for each drug. The 
LDL/VLDL-fraction was extracted from the pooled samples using an LDL/VLDL 
Purification Kit (Cell Biolabs, San Diego, CA, USA), according to the manufacturer’s 
instructions. Briefly, LDL/VLDL were precipitated by adding dextran, which was 
subsequently removed by several washing steps. In order to confirm VLDL/LDL isolation 
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and albumin in eight samples using photometry (Roche method ACN 8552, Instrument: 
Cobas c702, Roche, Basel, Switzerland). 
DRUG MEASUREMENTS 
Samples for drug measurements were prepared by protein precipitation using a Hamilton 
STARlet (Hamilton Robotics, Martinsried, Germany) and analyzed on an Agilent 
Technologies 6490 triple quadrupole liquid chromatography tandem mass spectrometry (LC-
MS/MS) operated at positive electrospray ionization and a 1290 Infinity LC-system (Agilent 
Technologies, Waldbronn, Germany). Calibrator sets (MassTox Antidepressants 1, 
Neuroleptics 1 and Neuroleptics 2) were supplied from Chromsystems (Chromsystems 
Instruments & Chemicals GmbH, Gräfelfing, Germany). The method was validated 
according to ISO 15189.19 The coefficient of variation (CV) for the respective analytes was in 
the range of 3.06 % to 6.69 % with an average of 4.13 %. The PAMPA-samples were 
analyzed, after dilution to fit within the standard curve, by LC-MS/MS using a Sciex QTRAP 
6500+ (Sciex, Concord, ON, Canada).  
PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY (PAMPA) 
Compound solutions were prepared by diluting 20 mM of drug stock solutions [in dimethyl 
sulfoxide (DMSO)] in phosphate buffered saline (PBS) (pH 7.4) to a final concentration of 50 
µM. Passive diffusion across an artificial membrane was measured using the PAMPA kit 
from Corning Gentest (Bedford, MA, USA), according to the manufacturer’s instructions. In 
summary, a 96-well filter plate, pre-coated with lipids, was used as the permeation acceptor 
and a matching 96-well receiver plate was used as the permeation donor. To confirm the 
integrity of the membrane separating the donor wells from the acceptor wells, we used 
doxorubicin as an impermeable control substance, and chlorpromazine as a highly permeable 
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were measured and the membrane permeability calculated. The membrane permeability is 
measured in centimeters per second and presented as logarithmic values (Log Pe). Based on 
this parameter, the following categorization of perm ability has been suggested: High (> 
−5.33), intermediate (> −5.66 and < −5.33), low (> −6.14 and < −5.66) and impermeable 
(←6.14).20 The pH value in the donor wells was measured using a photometric method on a 
Beckman Coulter AU680 (Bekman Coulter, Brea, CA, USA).  
CALCULATIONS 
All physico-chemical parameters [octanol:water partition coefficient (logP), polar surface 
area (PSA), protein binding (PB)] and logarithmic acid dissociation constant (pKa) were 
extracted from Drug Bank.21 Because of lack of data, the PB of levomepromazine was 
assumed to be the same as alimemazine, based on structural similarities. The compatibility 
factor (CF), as presented in a paper regarding gel separator tubes,22 for each drug was 
calculated using the following formula:  
CF = ((logP)2*PB)/PSA  (eq. 1) 
The ratio between the concentration measured in the LDL/VLDL fractions and the 
concentration measured in the initial serum pools (L/S-ratio) was also estimated for each 
drug.  
Regarding the PAMPA results, the permeability (cm/s) of the compounds were calculated 
using the following formula:  
Pe = {-ln[1-CA(t)/Ceq]}/[A*(1/V D+1/VA)*t]  (eq. 2) 
where A = filter area (0.3 cm2), VD = donor well volume (0.3 mL), VA = acceptor well 
volume (0.2 mL), t = incubation time (seconds), CA(t) = compound concentration in acceptor 
well at time t, CD(t) = compound concentration in donor well at time t, and  
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STATISTICS 
All statistical analyses were conducted using IBM SPS  statistics for Apple ver. 25 (IBM, 
Armonk, NY, USA). A p value < 0.05 was required to achieve a statistical significance. To 
investigate whether logP, PB, PSA or CF was correlated with the presence of drugs in 
lipoproteins or not, we performed a nonparametric Mann-Whitney U test, with the null 
hypotheses that the distribution of logP, PB, PSA and CF of the drugs included in the study 
was equal in the drugs found in lipoproteins as for th se not present in lipoproteins. To 
investigate the impact the three independent parameters have on lipoprotein association, a 
ternary plot was created, using the SigmaPlot software ver. 9.0 (Systat Software, San Jose, 
CA, USA).  
ETHICS 
The study was performed using disposable, pooled TDM samples, with no possibility of 
identifying the individual patients.  
 
Results and Discussion 
Successful purification of LDL/VLDL was confirmed by measurements of LDL and albumin 
in randomly selected samples after LDL/VLDL fractionation. In these LDL/VLDL fractions, 
high concentrations of LDL (14.2-17.8 mmol/L) and albumin concentrations below the 
detection limit (2 g/L) were found (data not shown).  
Out of the 20 antidepressants, antipsychotics and antiepileptics examined, seven drugs were 
detected both in the pooled serum samples and in the LDL/VLDL fraction extracted from the 
same samples (Table 1). Four were antidepressants (ser raline, amitriptyline, fluoxetine and 
paroxetine) and three were antipsychotics (levomepromazine, aripiprazole and clozapine). 
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(nmol/L): sertraline: 281/428, amitriptyline: 245/30, fluoxetine: 487/193, paroxetine: 168/24, 
levomepromazine: 10/3, aripiprazole: 245/30, clozapine: 2342/94. None of the antiepileptic 
agents were present in LDL/VLDL.  
The concentrations in the LDL/VLDL fractions suggest that for some agents, a significant 
proportion may be associated with LDL/VLDL particles in vivo. Interestingly, sertraline was 
found in a higher concentration in the LDL/VLDL fractions than in the respective serum 
pools. For all seven substances detected in the LDL/VLDL fractions, we observed a tendency 
towards a higher logP with higher ratios between the concentrations in LDL/VLDL and 
serum (L/S ratio, Table 1). 
By further examining the influence of the drugs’ physico-chemical properties, we found that 
association of drugs with LDL/VLDL significantly correlated with high logP value, high 
degree of protein binding, and a low polar surface rea (Figure 1A-D, Mann-Whitney U test: 
p < 0.001). We therefore plotted the values of the thr e physico-chemical parameters of each 
drug analyzed into a ternary plot to see if the drugs associated with the lipoproteins had 
similar properties, i.e. if the contribution of each physico-chemical parameter was similar for 
each drug (Figure 1E). In this plot, we noticed a clear cluster of drugs associated with 
LDL/VLDL, where the strongest determining factor was high logP, and low PSA. The impact 
of protein binding was less evident. These findings connect with an intuitive assumption: 
That substances with low polarity and highly fat solubility are prone to associate with 
lipoproteins when present in blood. The drugs not associated with the lipoproteins were 
scattered throughout the plot, and no common characteristic could be found for these. 
Haloperidol, which shares the criteria of the drugs detected in the LDL/VLDL fraction, was 
not detected in lipoproteins. However, the reference range for haloperidol is low compared to 
the other psychotropic drugs. It might therefore be that the drug is below the detection limit 
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The compatibility factor (CF, eq. 1) has been suggested as an indicator for determining 
whether a drug would bind to the lipophilic gel in gel separator tubes.22 According to our 
results, the CF also correlated with high lipoprotein association, as expected since the CF is a 
function of the three physico-chemical parameters mentioned above. However, it is 
noteworthy that in the equation for CF, the value of logP is squared. As a consequence, a 
positive and negative logP will yield the same value, contributing equally to the CF value. 
This factor can thus only be used if all the drugs to be compared have a logP value above 
zero. As seen from Table 1, one of our drugs had a neg tive logP (levetiracetam; logP = - 
0.60), and the CF may not to be a fully adequate predictor in determining drug association to 
lipoproteins. 
According to the classification detailed in the “Materials and Methods” section, PAMPA 
results demonstrated that six of the seven drugs found in LDL/VLDL had a high or 
intermediate membrane permeability, while aripiprazole came out as impermeable in our 
study (Table 1). One might suspect that aripiprazole did not permeate the membrane because 
it was present in an ionized form. We therefore measured the pH value in the donor wells, 
which was close to 7.4 in all wells (data not shown). This is close to the pKa for aripiprazole 
(7.46). However, the pKa value of quetiapine (7.06) and clozapine (7.5) also lie close to this 
value, and both of these substances were found to be highly permeable. The pH value in the 
donor wells therefore cannot explain the impermeability of aripiprazole. Another explanation 
could be that aripiprazole is trapped in the membrane, hinting that its association with 
lipoprotein is in the phospholipid layer, rather than the triglyceride and cholesterol containing 
core. This could not be determined by means of the PAMPA assay. 
In a previous report, the permeability of four of the drugs included in the present study 
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values calculated by us deviate somewhat from these findings, all drugs fell into the same 
suggested permeation categories (high or intermediate). 
With regard to limitations, the samples used in this study had been stored for seven days at 
4°C before LDL/VLDL fractionation and drug analysis. This may have influenced how drugs 
distribute to LDL/VLDL. Furthermore, we have no information about the patients’ medical 
history, or the sampling circumstances. However, the serum pool drug concentrations were 
all within the respective reference ranges common in standardized TDM. Furthermore, in 
order to be able to compare 20 drugs, the number of biological replicates was limited to one. 
In future experiments, the number of parallels should be significantly increased to strengthen 
the basis of the conclusions. 
 
Conclusions 
In this pilot study, we showed that several psychotropic drugs are associated with 
LDL/VLDL isolated from human serum. Our results support the model suggested by 
Yamamoto et al., with total measured drug concentrations representing the sum of not only 
free and protein-bound drug, but the sum of free, protein-bound and lipoprotein-bound 
drug.12 
The drugs found in LDL/VLDL were all characterized by a high logP value, high degree of 
protein binding, and a low polar surface area. With the exception of aripiprazole, they were 
also characterized by high or intermediate membrane permeability.  
The association of drugs with lipoproteins may have wide-ranging consequences. It has been 
suggested that lipoprotein-associated drug transport h uld be distinguished from protein-
bound transport due to the ability of lipoproteins to be transferred into tissues and cells 
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If drugs follow lipoproteins into relevant tissues, they may reach a higher tissue concentration 
than assumed based on the size of the free fraction in blood, with implications for effect and 
side effect profiles alike. This implies that the con entration of LDL and VLDL in blood 
could be of importance for the tissue concentration of drugs. Furthermore, co-administration 
of statins, shown to increase the expression of LDLreceptors,24 may potentially influence the 
biodistribution and effect of a drug associated to lip proteins. 
Further research is needed to evaluate whether distribution into VLDL/LDL affects the 
cellular uptake of psychotropic drugs, and which pharmacological and/or clinical 
consequences this may have. Importantly, revealing the details of distribution of lipophilic 
drugs to lipoproteins may also contribute to the development of artificial lipoproteins for 
targeted delivery of pharmacological agents.25, 26 
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Figure Legend 
Figure 1. Relationship between different physico-chemical properties of drugs and their 
ability to associate with lipoproteins. A-D: The drugs were classified as either found in 
lipoproteins, or not found in lipoproteins, and histograms created based on the frequency 
(number) of the drugs at the following physico-chemical properties: Polar surface area (A), 
Protein Binding (B), logP (C), and Compatibility factor (logarithmic) (logCF). E: Ternary 
plot showing the influence of polar surface area, protein binding, and logP on the drugs 
present in the LDL/VLDL fraction (filled circles) or drugs not found in the LDL/VLDL 
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TABLE 1. Physico-chemical properties of antidepressants, antipsychotics and antiepileptics, and 
distribution to LDL/VLDL in human serum. 








       
  
Antidepressants 
      
  
Sertraline 5.10 98 12.0 212.4 X 1.51 -5.51 Intermediate 
Amitriptyline 4.92 97 3.2 733.8 X 0.17 -5.24 High 
Fluoxetine 4.05 95 21.3 74.2 X 0.40 -5.26 High 
Paroxetine 3.60 95 39.7 30.8 X 0.14 -5.30 High 
Escitalopram 3.50 56 36.2 18.9 
 
  
Venlafaxine 3.20 30 32.7 9.4 
 
  
Mirtazapine 2.90 85 19.4 3.9 
 
  
       
  
Antipsychotics 
     
  
Levomepromazine 4.70 90 15.7 124.3 X 0.32 -5.40 Intermediate 
Aripiprazole 4.50 99 44.8 44.6 X 0.13 -8.83 Impermeable 
Haloperidol 4.30 92 40.5 42.0 
 
   
Clozapine 3.20 95 30.9 31.4 X 0.06 -5.24 High 
Quetiapine 2.80 83 48.3 13.5 
 
   
Risperidone 2.50 88 61.9 8.9 
 
   
Olanzapine 2.00 93 30.9 12.0 
 
   
Paliperidone 1.80 74 82.2 2.9 
 
   
Amisulpride 1.06 17 101.7 0.2 
 
   
       
   
Antiepileptics 
     
   
Valproic acid 2.75 90 37.3 18.2 
 
   
Lamotrigine 2.50 55 90.7 3.8 
 
   
Carbamazepine 2.45 76 46.3 9.9 
 
   
Levetiracetam - 0.60 10 63.4 0 
 
   
      
   
Table 1. LDL = low density lipoprotein; VLDL = very low density lipoprotein; logP = partition coefficient; PB = protein binding in 
percent; PSA = polar surface area; CF (compatibility factor) = ((logP)2*PB)/PSA; L/S-ratio (lipoprotein-drug-ratio) = drug concentration 
in LDL-VLDL/drug concentration in serum (mean value, amitriptyline: n=2, fluoxetine: n=2, paroxetine: n=3, sertraline: n=2, 
aripiprazole: n=3, clozapine: n=2, levomepromazine: n=2). LogPe = the logarithmic value of the membrane permeability (cm/s) (mean 
value: clozapine: n=3, amitriptyline: n=3, paroxetine: n=3, levomepromazine: n=3, aripiprazole: n=3, fluoxetine: n=2, sertraline: n=2). 
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FIGURE 1. Relationship between different physico-chemical properties of drugs and their ability to associate with lipoproteins. A-D: The 
drugs were classified as either found in lipoproteins, or not found in lipoproteins, and histograms created based on the frequency (number) of 
the drugs at the following physico-chemical properties: Polar surface area (A), Protein Binding (B), logP (C), and Compatibility factor 
(logarithmic) (logCF). E: Ternary plot showing the influence of polar surface area, protein binding, and logP on the drugs present in the 
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